Wire Stories
OliX Pharmaceuticals Administers First Patient in Phase 1 Clinical Study of RNAi Therapeutic OLX72021 for Androgenic Alopecia
SUWON, South Korea–(BUSINESS WIRE)–#AndrogenicAlopecia—OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced today that the first patient has been...